ERBB2 and breast carcinoma: These findings are crucial in understanding the molecular mechanisms underlying migration in HER2-positive breast cancer cells and drug resistance, providing a foundation for developing novel and more specific therapeutic strategies to disrupt the progression and metastasis of HER2-positive breast cancer (46).